The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
siRNA: Mechanism of action, challenges, and therapeutic approaches
Abstract
Owing to specific and compelling gene silencing, RNA interference (RNAi) is expected to become an essential approach in treating a variety of infectious, hemato-oncological, cardiovascular, and neurodegenerative conditions. The mechanism of action of small interfering RNA (siRNA) is based on post-transcriptional gene silencing. siRNA molecules are usually specific and efficient in the knockdown of disease-related genes. However, they are characterized by low cellular uptake and are susceptible to nuclease-mediated degradation. Therefore, siRNAs require a carrier for their protection and efficient delivery into target cells. The current review highlights the siRNA-based mechanism of action, challanges, and recent advances in clinical applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,018
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
TFOS DEWS II Definition and Classification Report
Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C.-K., Liu, Z., Nelson, J. D., Nichols, J. J., Tsubota, K., et al. (2017) · The Ocular Surface · doi:10.1016/j.jtos.2017.05.008 · Cited by 3,383
CRISPR–Cas9 Structures and Mechanisms
Jiang, F., & Doudna, J. A. (2017) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010822 · Cited by 2,029
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies
Gauglitz, G. G., Korting, H. C., Pavicic, T., Ruzicka, T., & Jeschke, M. G. (2011) · Molecular Medicine · doi:10.2119/molmed.2009.00153 · Cited by 1,462
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Illuminating the silence: understanding the structure and function of small RNAs
Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 1,083
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
siRNA function in RNAi: A chemical modification analysis
CHIU, Y.-L., & RANA, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 860
RNA-Based Therapeutics: Current Progress and Future Prospects
Burnett, J. C., & Rossi, J. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.008 · Cited by 819
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Liposomal Drug Delivery Systems and Anticancer Drugs
Olusanya, T., Haj Ahmad, R., Ibegbu, D., Smith, J., & Elkordy, A. (2018) · Molecules · doi:10.3390/molecules23040907 · Cited by 603
Familial adenomatous polyposis
Half, E., Bercovich, D., & Rozen, P. (2009) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-4-22 · Cited by 596
Tolerance for mutations and chemical modifications in a siRNA
Amarzguioui, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg147 · Cited by 534
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
Aye, Y., Li, M., Long, M. J. C., & Weiss, R. S. (2015) · Oncogene · doi:10.1038/onc.2014.155 · Cited by 436
Zuckerman, J. E., Gritli, I., Tolcher, A., Heidel, J. D., Lim, D., Morgan, R., Chmielowski, B., Ribas, A., Davis, M. E., & Yen, Y. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411393111 · Cited by 427
Improved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
Self-citationRNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
Pasi, K. J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T., Bevan, D., Austin, S., Hay, C. R., Hegemann, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616569 · Cited by 367
Friedrich Miescher and the discovery of DNA
Dahm, R. (2005) · Developmental Biology · doi:10.1016/j.ydbio.2004.11.028 · Cited by 362
Programmable CRISPR-responsive smart materials
English, M. A., Soenksen, L. R., Gayet, R. V., de Puig, H., Angenent-Mari, N. M., Mao, A. S., Nguyen, P. Q., & Collins, J. J. (2019) · Science · doi:10.1126/science.aaw5122 · Cited by 356
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Novellasdemunt, L., Antas, P., & Li, V. S. W. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00117.2015 · Cited by 339
Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4183 · Cited by 336
Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Scholz, C., & Wagner, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.014 · Cited by 333
Connective tissue growth factor (CTGF) from basics to clinics
Ramazani, Y., Knops, N., Elmonem, M. A., Nguyen, T. Q., Arcolino, F. O., van den Heuvel, L., Levtchenko, E., Kuypers, D., & Goldschmeding, R. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.007 · Cited by 329
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 291
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.273 · Cited by 265
Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0376 · Cited by 260
Yoshida, T., Mett, I., Bhunia, A. K., Bowman, J., Perez, M., Zhang, L., Gandjeva, A., Zhen, L., Chukwueke, U., Mao, T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2157 · Cited by 234
Getting Syk: spleen tyrosine kinase as a therapeutic target
Geahlen, R. L. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.007 · Cited by 229
A protocol for designing siRNAs with high functionality and specificity
Birmingham, A., Anderson, E., Sullivan, K., Reynolds, A., Boese, Q., Leake, D., Karpilow, J., & Khvorova, A. (2007) · Nature Protocols · doi:10.1038/nprot.2007.278 · Cited by 222
Current issues of RNAi therapeutics delivery and development
Haussecker, D. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.056 · Cited by 217
Clinical and Pathological Features of Pachyonychia Congenita
Leachman, S. A., Kaspar, R. L., Fleckman, P., Florell, S. R., Smith, F. J. D., McLean, W. H. I., Lunny, D. P., Milstone, L. M., van Steensel, M. A. M., Munro, C. S., et al. (2005) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1111/j.1087-0024.2005.10202.x · Cited by 209
Bronchiolitis Obliterans Syndrome
Todd, J. L., & Palmer, S. M. (2011) · Chest · doi:10.1378/chest.10-2838 · Cited by 197
RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Kaiser, P. K., Symons, R. C. A., Shah, S. M., Quinlan, E. J., Tabandeh, H., Do, D. V., Reisen, G., Lockridge, J. A., Short, B., Guerciolini, R., et al. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.02.006 · Cited by 195
Precise and efficient siRNA design: a key point in competent gene silencing
Fakhr, E., Zare, F., & Teimoori-Toolabi, L. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.4 · Cited by 191
Efficient nanocarriers of siRNA therapeutics for cancer treatment
Subhan, M. A., & Torchilin, V. P. (2019) · Translational Research · doi:10.1016/j.trsl.2019.07.006 · Cited by 183
Ui-Tei, K., Naito, Y., Zenno, S., Nishi, K., Yamato, K., Takahashi, F., Juni, A., & Saigo, K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn042 · Cited by 176
Gottlieb, J., Zamora, M. R., Hodges, T., Musk, A. W., Sommerwerk, U., Dilling, D., Arcasoy, S., DeVincenzo, J., Karsten, V., Shah, S., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.08.012 · Cited by 169
Cobb, M. (2015) · Current Biology · doi:10.1016/j.cub.2015.05.032 · Cited by 167
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001997 · Cited by 165
Saraswathy, M., & Gong, S. (2014) · Materials Today · doi:10.1016/j.mattod.2014.05.002 · Cited by 163
Basic Techniques in Mammalian Cell Tissue Culture
Phelan, K., & May, K. M. (2015) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0101s66 · Cited by 162
Kraynack, B. A., & Baker, B. F. (2005) · RNA · doi:10.1261/rna.2150806 · Cited by 159
Chemical and structural modifications of RNAi therapeutics
Ku, S. H., Jo, S. D., Lee, Y. K., Kim, K., & Kim, S. H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.015 · Cited by 155
siRNA based drug design, quality, delivery and clinical translation
Subhan, M. A., & Torchilin, V. P. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102239 · Cited by 154
Delivery strategies and potential targets for siRNA in major cancer types
Lee, S. J., Kim, M. J., Kwon, I. C., & Roberts, T. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.010 · Cited by 153
Short Hairpin RNA-Mediated Gene Silencing
Lambeth, L. S., & Smith, C. A. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_12 · Cited by 152
Kubiak, K., Sochacka, E., Kaźmierczak-Barańska, J., Maszewska, M., Janicka, M., Nowak, G., & Nawrot, B. (2007) · RNA · doi:10.1261/rna.538907 · Cited by 150
Alshaer, W., Hillaireau, H., Vergnaud, J., Mura, S., Deloménie, C., Sauvage, F., Ismail, S. I., & Fattal, E. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.022 · Cited by 147
Self-citationWu, S. Y., Yang, X., Gharpure, K. M., Hatakeyama, H., Egli, M., McGuire, M. H., Nagaraja, A. S., Miyake, T. M., Rupaimoole, R., Pecot, C. V., et al. (2014) · Nature Communications · doi:10.1038/ncomms4459 · Cited by 146
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Hashemi, F., Moghadam, E. R., Owrang, M., Hashemi, F., Makvandi, P., Goharrizi, M. A. S. B., Najafi, M., et al. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109871 · Cited by 142
Dande, P., Prakash, T. P., Sioufi, N. B., Gaus, H. J., Jarres, R., Berdeja, A., Swayze, E. E., Griffey, R. H., & Bhat, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050822c · Cited by 138
High potency silencing by single-stranded boranophosphate siRNA
Hall, A., Wan, J., Spesock, A., Sergueeva, Z. A., Shaw, B. R., & Alexander, K. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl339 · Cited by 124
Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy
Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Hashemi, F., Moghadam, E. R., Raei, M., Kalantari, M., Tavakol, S., Mohammadinejad, R., Najafi, M., et al. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00099 · Cited by 119
Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines
Park, J., Park, J., Pei, Y., Xu, J., & Yeo, Y. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.004 · Cited by 116
Novel ribozymes: discovery, catalytic mechanisms, and the quest to understand biological function
Weinberg, C. E., Weinberg, Z., & Hammann, C. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz737 · Cited by 116
Butt, A. M., Amin, M. C. I. M., Katas, H., Murad, N. A. A., Jamal, R. A., & Kesharwani, P. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00776 · Cited by 115
Dumbbell-Shaped Nanocircular RNAs for RNA Interference
Abe, N., Abe, H., & Ito, Y. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0754453 · Cited by 105
Respiratory Viral Infections in Hematopoietic Stem Cell and Solid Organ Transplant Recipients
Weigt, S. S., Gregson, A. L., Deng, J. C., Lynch, J. P., & Belperio, J. A. (2011) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0031-1283286 · Cited by 103
Chemical Modification of siRNA
Deleavey, G. F., Watts, J. K., & Damha, M. J. (2009) · Current Protocols in Nucleic Acid Chemistry · doi:10.1002/0471142700.nc1603s39 · Cited by 101
Nguyen, Q. D., Schachar, R. A., Nduaka, C. I., Sperling, M., Basile, A. S., Klamerus, K. J., Chi-Burris, K., Yan, E., Paggiarino, D. A., Rosenblatt, I., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9961 · Cited by 101
Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease: Figure 1:
Brode, S. K., Ling, S. C., & Chapman, K. R. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.111749 · Cited by 101
Delivery Strategies for siRNA-mediated Gene Silencing
Gilmore, I. R., Fox, S. P., Hollins, A. J., et al. (2006) · Current Drug Delivery · doi:10.2174/156720106776359159 · Cited by 99
Tivanisiran, a novel siRNA for the treatment of dry eye disease
Moreno‐Montañés, J., Bleau, A., & Jiménez, A. I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1457647 · Cited by 97
Bissell, D. M., & Wang, B. (2015) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00039 · Cited by 96
RNA interference induced by siRNAs modified with 4′‐thioribonucleosides in cultured mammalian cells
Hoshika, S., Minakawa, N., Kamiya, H., Harashima, H., & Matsuda, A. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.04.073 · Cited by 94
Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics
Hyeon, L. S., Kang, Y. Y., Jang, H.-E., & Mok, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.009 · Cited by 93
Basic Techniques in Mammalian Cell Tissue Culture
Phelan, M. C. (2007) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0101s36 · Cited by 87
siRNAmod: A database of experimentally validated chemically modified siRNAs
Dar, S. A., Thakur, A., Qureshi, A., & Kumar, M. (2016) · Scientific Reports · doi:10.1038/srep20031 · Cited by 82
Mutisya, D., Selvam, C., Lunstad, B. D., Pallan, P. S., Haas, A., Leake, D., Egli, M., & Rozners, E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku235 · Cited by 64
Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA
Raja, M. A. G., Katas, H., & Amjad, M. W. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.12.005 · Cited by 58
Demirjian, S., Ailawadi, G., Polinsky, M. S., Bitran, D., Silberman, S., Shernan, S. K., Burnier, M., Hamilton, M., Squiers, E. C., Erlich, S. S., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.03.016 · Cited by 46
Recent Advances of Polycationic siRNA Vectors for Cancer Therapy
Bholakant, R., Qian, H., Zhang, J., Huang, X., Huang, D., Feijén, J., Zhong, Y., & Chen, W. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00438 · Cited by 43
Complement disorders and hemolytic uremic syndrome
Joseph, C., & Gattineni, J. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32835df48a · Cited by 42
Genetic Diseases of the Kidney
(2009) · Elsevier eBooks · doi:10.1016/b978-0-12-449851-8.x0001-0 · Cited by 38
Pathogenesis of Cancer: Cancer Reparative Trap
Bukhtoyarov, O. V., & Самарин, Д. М. (2015) · Journal of Cancer Therapy · doi:10.4236/jct.2015.65043 · Cited by 37
Comparing 2-nt 3' overhangs against blunt-ended siRNAs: a systems biology based study
Ghosh, P., Dullea, R., Fischer, J. E., Turi, T., Sarver, R. W., Zhang, C., Basu, K., Das, S. K., & Poland, B. W. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-s1-s17 · Cited by 34
Maguregui, A., & Abe, H. (2020) · ChemBioChem · doi:10.1002/cbic.202000009 · Cited by 26
Gillmore, J. D., Falk, R. H., Maurer, M. S., Hanna, M. A., Karsten, V., Vest, J., Gollob, J., & Hawkins, P. N. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-10-s1-o21 · Cited by 17
A Novel Method for Controlled Gene Expression via Combined Bleomycin and Plasmid DNA Electrotransfer
Chopra, S., Ruzgys, P., Jakutavičiūtė, M., Rimgailaitė, A., Navickaitė, D., & Šatkauskas, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164047 · Cited by 9
Renaud-Picard, B., Vallière, K., Toussaint, J., Kreutter, G., Habhab, A. E., Kassem, M., El-Ghazouani, F., Olland, A., Hirschi, S., Porzio, M., et al. (2020) · Transplant Immunology · doi:10.1016/j.trim.2020.101273 · Cited by 8
Rationale design of polymeric siRNA delivery systems
Kim, N., Lim, T. H., Behlke, M. A., Salem, A. K., Grosland, N. M., & Park, J. B. (2011) · doi:10.17077/etd.6zoanbuf · Cited by 2
Cited by
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Albosta, M. S., Grant, J. K., Taub, P., Blumenthal, R. S., Martin, S. S., & Michos, E. D. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s338424 · Cited by 51
Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA
Alla, S. S. M., Shah, D. J., Meyur, S., Agarwal, P., Alla, D., Moraboina, S. L., Ghadvaje, G. V., Bayeh, R. G., Malireddi, A., Shajan, T., et al. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s521579 · Cited by 4
Metadata
- Authors
- Alshaer, W., Zureigat, H., Al Karaki, A., Al-Kadash, A., Gharaibeh, L., Hatmal, M. M., Aljabali, A. A. A., & Awidi, A.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 905
- Pages
- 174178
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W3165627834
- Cited by
- 441
- References
- 94
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.